Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14680143 | 0.86 | MAOB (0.57) | MAOBMAOAFFAR1MTNR1AMTNR1B | |
| SCHEMBL6450178 | 0.85 | LRRK2 (0.60) | MAOBMEN1KMT2ALMNA | |
| SCHEMBL29707531 | 0.85 | LRRK2 (0.60) | MAOBMEN1KMT2ALMNA | |
| SCHEMBL22454497 | 0.84 | FFAR4 (0.45) | MAOBMAOAFFAR1FFAR4MTNR1A | |
| SCHEMBL29684452 | 0.84 | FFAR4 (0.45) | MAOBMAOAFFAR1FFAR4MTNR1A | |
| SCHEMBL31658724 | 0.83 | SMN1; SMN2 (0.57) | MAOBMEN1KMT2ALMNAHTT | |
| SCHEMBL4938231 | 0.83 | SMN1; SMN2 (0.57) | MAOBMEN1KMT2ALMNAHTT | |
| SCHEMBL14680155 | 0.82 | MAOB (0.56) | MAOBMAOAMEN1KMT2AMTNR1A | |
| SCHEMBL2477376 | 0.81 | FFAR4 (0.73) | MAOBMAOAFFAR1FFAR4MEN1 | |
| SCHEMBL8888358 | 0.81 | LRRK2 (0.63) | MAOBMTNR1AMTNR1BHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028352-A1 | MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SUZHOU LANGRUI BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| EP-4585598-A1 | MACROCYCLIC IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Suzhou Langrui Biopharmaceutical Co., Ltd. (CN) | 2025-07-16 | — | — | EP | disclosed |
| EP-3932923-B1 | PYRAZOLOPYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREFOR | UNIV CENTRAL CHINA NORMAL (CN) | 2023-05-03 | — | — | EP | disclosed |
| EP-3932923-B1 | PYRAZOLOPYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREFOR | UNIV CENTRAL CHINA NORMAL (CN) | 2023-05-03 | — | — | EP | disclosed |
| US-20220177477-A1 | PYRAZOLOPYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREFOR | Central China Normal University (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20220177477-A1 | PYRAZOLOPYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREFOR | Central China Normal University (CN) | 2022-06-09 | — | — | US | disclosed |
| EP-3932923-A1 | PYRAZOLOPYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREFOR | Central China Normal University (CN) | 2022-01-05 | — | — | EP | disclosed |
| WO-2020187291-A1 | PYRAZOLOPYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREFOR | 华中师范大学 | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177477-A1 | PYRAZOLOPYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREFOR | ITK, TKFC, WEE2 | MAOB 3217/4885MAOA 3218/4885FFAR1 451/4885 |
| US-20260028352-A1 | MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | WEE2, WEE1, ROR1 | MAOB 3142/4885MAOA 3991/4885FFAR1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.